Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
- 20 August 2013
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 28 (1) , 222-225
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer OutcomeClinical Cancer Research, 2013
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working GroupLeukemia, 2012
- Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocolsLeukemia, 2012
- Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution ExperienceClinical Lymphoma Myeloma and Leukemia, 2011
- Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant ResearchLeukemia, 2011
- Primary plasma cell leukemia: a retrospective multicenter study of 73 patientsAnnals of Oncology, 2011
- Primary plasma cell leukemia and autologous stem cell transplantationHaematologica, 2010
- Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemiaLeukemia Research, 2008
- Efficacy and safety of bortezomib in patients with plasma cell leukemiaCancer, 2007
- Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem‐cell transplantation and review of the literatureAmerican Journal of Hematology, 2005